<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_R5wsVFE">Effectiveness of a Multifaceted Informational-Based and Text Message Reminders on Pneumococcal and Influenza Vaccinations in Hospital Emergency Departments: A Cluster-Randomized Controlled Trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).</p>
				</availability>
				<date type="published" when="2021-08-28">28 August 2021</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Sarah</forename><surname>Tubiana</surname></persName>
							<email>sarah.tubiana@aphp.fr</email>
							<idno type="ORCID">0000-0002-6526-6403</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> AP-HP , Hôpital Bichat , Centre d&apos;Investigation Clinique , INSERM CIC 1425 , F-75018 Paris , France;</note>
								<orgName type="department">Centre d&apos;Investigation Clinique</orgName>
								<orgName type="laboratory">AP-HP</orgName>
								<orgName type="institution" key="instit1">Hôpital Bichat</orgName>
								<orgName type="institution" key="instit2">INSERM CIC</orgName>
								<address>
									<addrLine>1425</addrLine>
									<postCode>F-75018</postCode>
									<settlement>Paris</settlement>
									<country>France;</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Université de Paris , IAME , INSERM , F-75018 Paris , France</note>
								<orgName type="institution" key="instit1">Université de Paris</orgName>
								<orgName type="institution" key="instit2">IAME</orgName>
								<orgName type="institution" key="instit3">INSERM</orgName>
								<address>
									<postCode>F-75018</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">José</forename><surname>Labarere</surname></persName>
							<email>jlabarere@chu-grenoble.fr</email>
							<idno type="ORCID">0000-0001-7621-6586</idno>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Université de Grenoble Alpes/CNRS / TIMC UMR 5525 , F-38041 Grenoble , France;</note>
								<orgName type="laboratory">UMR 5525</orgName>
								<orgName type="institution" key="instit1">Université de Grenoble Alpes/CNRS</orgName>
								<orgName type="institution" key="instit2">TIMC</orgName>
								<address>
									<postCode>F-38041</postCode>
									<settlement>Grenoble</settlement>
									<country>France;</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Grenoble University Hospital , F-38043 Grenoble , France</note>
								<orgName type="institution">Grenoble University Hospital</orgName>
								<address>
									<postCode>F-38043</postCode>
									<settlement>Grenoble</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jacques</forename><surname>Levraut</surname></persName>
							<email>levraut.j@chu-nice.fr</email>
							<idno type="ORCID">0000-0001-7621-6586</idno>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> CHU de Nice , Département de Médecine d&apos;Urgence , Hôpital Pasteur-II , F-06001 Nice , France;</note>
								<orgName type="department">Département de Médecine d&apos;Urgence</orgName>
								<orgName type="institution" key="instit1">CHU de Nice</orgName>
								<orgName type="institution" key="instit2">Hôpital Pasteur-II</orgName>
								<address>
									<postCode>F-06001</postCode>
									<settlement>Nice</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pierre</forename><surname>Michelet</surname></persName>
							<email>pierre.michelet@ap-hm.fr</email>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>6</label> AP-HM , Hôpital la Timone , Département de Médecine d&apos;Urgence , UMR C2VN-Aix Marseille Université , F-13005 Marseille , France;</note>
								<orgName type="department" key="dep1">AP-HM</orgName>
								<orgName type="department" key="dep2">Département de Médecine d&apos;Urgence</orgName>
								<orgName type="institution" key="instit1">Hôpital la Timone</orgName>
								<orgName type="institution" key="instit2">UMR C2VN-Aix Marseille Université</orgName>
								<address>
									<postCode>F-13005</postCode>
									<settlement>Marseille</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fleur</forename><surname>Jourda De Vaux</surname></persName>
							<email>fleur.jourda-de-vaux@ap-hm.fr</email>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> EMSP et Urgences Adultes - Hôpital Nord-APHM , F-13015 Marseille , France;</note>
								<orgName type="department">EMSP et Urgences Adultes</orgName>
								<orgName type="institution">Hôpital Nord-APHM</orgName>
								<address>
									<postCode>F-13015</postCode>
									<settlement>Marseille</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Benoit</forename><surname>Doumenc</surname></persName>
							<email>benoit.doumenc@aphp.fr</email>
							<affiliation key="aff7">
								<note type="raw_affiliation"><label>8</label> AP-HP , Hôpital Cochin , Services d&apos;Accueil des Urgences , F-75014 Paris , France;</note>
								<orgName type="department" key="dep1">AP-HP</orgName>
								<orgName type="department" key="dep2">Services d&apos;Accueil des Urgences</orgName>
								<orgName type="institution">Hôpital Cochin</orgName>
								<address>
									<postCode>F-75014</postCode>
									<settlement>Paris</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pierre</forename><surname>Hausfater</surname></persName>
							<email>pierre.hausfater@aphp.fr</email>
							<affiliation key="aff8">
								<note type="raw_affiliation"><label>9</label> AP-HP , Hôpital Pitié-Salpêtrière , Services d&apos;Accueil des Urgences , GRC-14 BIOSFAST Sorbonne Université , F-75651 Paris , France;</note>
								<orgName type="department" key="dep1">Services d&apos;Accueil des Urgences</orgName>
								<orgName type="department" key="dep2">GRC-14</orgName>
								<orgName type="laboratory">AP-HP</orgName>
								<orgName type="institution" key="instit1">Hôpital Pitié-Salpêtrière</orgName>
								<orgName type="institution" key="instit2">BIOSFAST Sorbonne Université</orgName>
								<address>
									<postCode>F-75651</postCode>
									<settlement>Paris</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christophe</forename><surname>Choquet</surname></persName>
							<email>christophe.choquet@aphp.fr</email>
							<affiliation key="aff9">
								<note type="raw_affiliation"><label>10</label> AP-HP , Hôpital Bichat , Services d&apos;Accueil des Urgences , F-75018 Paris , France;</note>
								<orgName type="department" key="dep1">AP-HP</orgName>
								<orgName type="department" key="dep2">Services d&apos;Accueil des Urgences</orgName>
								<orgName type="institution">Hôpital Bichat</orgName>
								<address>
									<postCode>F-75018</postCode>
									<settlement>Paris</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><surname>Plaisance</surname></persName>
							<email>patrick.plaisance@aphp.fr</email>
							<affiliation key="aff10">
								<note type="raw_affiliation"><label>11</label> AP-HP , Hôpital Lariboisière , Services d&apos;Accueil des Urgences , F-75010 Paris , France;</note>
								<orgName type="department">Services d&apos;Accueil des Urgences</orgName>
								<orgName type="laboratory">AP-HP</orgName>
								<orgName type="institution">Hôpital Lariboisière</orgName>
								<address>
									<postCode>F-75010</postCode>
									<settlement>Paris</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jeannot</forename><surname>Schmid</surname></persName>
							<email>jschmidt@chu-clermontferrand.fr</email>
							<idno type="ORCID">0000-0003-3424-337X</idno>
							<affiliation key="aff11">
								<note type="raw_affiliation"><label>12</label> CHU de Clermont-Ferrand , Services d&apos;Accueil des Urgences , F-63003 Clermont-Ferrand , France;</note>
								<orgName type="department">Services d&apos;Accueil des Urgences</orgName>
								<orgName type="institution">CHU de Clermont-Ferrand</orgName>
								<address>
									<postCode>F-63003</postCode>
									<settlement>Clermont-Ferrand</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Véronique</forename><surname>Mattei</surname></persName>
							<email>v.mattei@ch-menton.fr</email>
							<idno type="ORCID">0000-0003-3424-337X</idno>
							<affiliation key="aff12">
								<note type="raw_affiliation"><label>13</label> CH de Menton , Services d&apos;Accueil des Urgences , F-06507 Menton , France;</note>
								<orgName type="department">Services d&apos;Accueil des Urgences</orgName>
								<orgName type="institution">CH de Menton</orgName>
								<address>
									<postCode>F-06507</postCode>
									<settlement>Menton</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olivier</forename><surname>Gacia</surname></persName>
							<email>olivier.gacia@intradef.gouv.fr</email>
							<affiliation key="aff13">
								<note type="raw_affiliation"><label>14</label> SSA , HIA Laveran , Services d&apos;Accueil des Urgences , F-13384 Marseille , France;</note>
								<orgName type="department">Services d&apos;Accueil des Urgences</orgName>
								<orgName type="laboratory">SSA</orgName>
								<orgName type="institution">HIA Laveran</orgName>
								<address>
									<postCode>F-13384</postCode>
									<settlement>Marseille</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Didier</forename><surname>Storme</surname></persName>
							<email>didier.storme@ch-vichy.fr</email>
							<affiliation key="aff14">
								<note type="raw_affiliation"><label>15</label> CH Jacques Lacarin , Services d&apos;Accueil des Urgences , F-03207 Vichy , France;</note>
								<orgName type="department">Services d&apos;Accueil des Urgences</orgName>
								<orgName type="institution">CH Jacques Lacarin</orgName>
								<address>
									<postCode>F-03207</postCode>
									<settlement>Vichy</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patri</forename><surname>Ray</surname></persName>
							<email>patrick.ray@chu-dijon.fr</email>
							<idno type="ORCID">0000-0001-8020-4975</idno>
							<affiliation key="aff15">
								<note type="raw_affiliation"><label>16</label> CHU Mitterrand , Département Universitaire de Médecine d&apos;Urgence , Université de Bourgogne , F-21000 Dijon , France;</note>
								<orgName type="department">Département Universitaire de Médecine d&apos;Urgence</orgName>
								<orgName type="institution" key="instit1">CHU Mitterrand</orgName>
								<orgName type="institution" key="instit2">Université de Bourgogne</orgName>
								<address>
									<postCode>F-21000</postCode>
									<settlement>Dijon</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Guillaume</forename><surname>Der Sahakian</surname></persName>
							<email>dersahakian@hotmail.fr</email>
							<idno type="ORCID">0000-0002-1594-5299</idno>
							<affiliation key="aff16">
								<note type="raw_affiliation"><label>17</label> Centre Hospitalier d&apos;Orange , FMI Nord Vaucluse , F-84104 Orange , France;</note>
								<orgName type="institution">Centre Hospitalier d&apos;Orange</orgName>
								<address>
									<addrLine>FMI Nord Vaucluse</addrLine>
									<postCode>F-84104</postCode>
									<settlement>Orange</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marie-Clément</forename><surname>Kouka</surname></persName>
							<email>marie-clement.kouka@ch-stdenis.fr</email>
							<idno type="ORCID">0000-0002-1594-5299</idno>
							<affiliation key="aff17">
								<note type="raw_affiliation"><label>18</label> Hôpital Delafontaine , Services d&apos;Accueil des Urgences , F-93200 Saint Denis , France;</note>
								<orgName type="department">Services d&apos;Accueil des Urgences</orgName>
								<orgName type="institution">Hôpital Delafontaine</orgName>
								<address>
									<postCode>F-93200</postCode>
									<settlement>Saint Denis</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Laure</forename><surname>Jainsky</surname></persName>
							<email>ljainsky@ch-issoire.fr</email>
							<affiliation key="aff18">
								<note type="raw_affiliation"><label>19</label> CH Paul Ardier Issoire , Services d&apos;Accueil des Urgences , F-63500 Issoire , France;</note>
								<orgName type="department">Services d&apos;Accueil des Urgences</orgName>
								<orgName type="institution">CH Paul Ardier Issoire</orgName>
								<address>
									<postCode>F-63500</postCode>
									<settlement>Issoire</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jocelyn</forename><surname>Raude</surname></persName>
							<email>jocelyn.raude@ehesp.fr</email>
							<idno type="ORCID">0000-0001-8020-4975</idno>
							<affiliation key="aff19">
								<note type="raw_affiliation"><label>20</label> EHESP-School of Public Health , F-35043 Rennes , France;</note>
								<orgName type="department">EHESP-School of Public Health</orgName>
								<address>
									<postCode>F-35043</postCode>
									<settlement>Rennes</settlement>
									<country>France;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xavier</forename><surname>Duval</surname></persName>
							<email>xavier.duval@aphp.fr</email>
							<idno type="ORCID">0000-0001-8020-4975</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> AP-HP , Hôpital Bichat , Centre d&apos;Investigation Clinique , INSERM CIC 1425 , F-75018 Paris , France;</note>
								<orgName type="department">Centre d&apos;Investigation Clinique</orgName>
								<orgName type="laboratory">AP-HP</orgName>
								<orgName type="institution" key="instit1">Hôpital Bichat</orgName>
								<orgName type="institution" key="instit2">INSERM CIC</orgName>
								<address>
									<addrLine>1425</addrLine>
									<postCode>F-75018</postCode>
									<settlement>Paris</settlement>
									<country>France;</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Université de Paris , IAME , INSERM , F-75018 Paris , France</note>
								<orgName type="institution" key="instit1">Université de Paris</orgName>
								<orgName type="institution" key="instit2">IAME</orgName>
								<orgName type="institution" key="instit3">INSERM</orgName>
								<address>
									<postCode>F-75018</postCode>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yann-Erick</forename><surname>Claessens</surname></persName>
							<email>yann-erick.claessens@chpg.mc</email>
							<affiliation key="aff20">
								<note type="raw_affiliation"><label>21</label> Hôpital Princesse Grâce , Service d&apos;accueil des Urgences , MC-98012 Monaco , Monaco;</note>
								<orgName type="department">Service d&apos;accueil des Urgences</orgName>
								<orgName type="institution">Hôpital Princesse Grâce</orgName>
								<address>
									<postCode>MC-98012</postCode>
									<settlement>Monaco</settlement>
									<country>Monaco;</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_yNwbekW">Effectiveness of a Multifaceted Informational-Based and Text Message Reminders on Pneumococcal and Influenza Vaccinations in Hospital Emergency Departments: A Cluster-Randomized Controlled Trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2021-08-28">28 August 2021</date>
						</imprint>
					</monogr>
					<idno type="MD5">019AD95270636723130B2F04F835FB42</idno>
					<idno type="DOI">10.3390/vaccines9090962</idno>
					<note type="submission">Received: 7 July 2021 Accepted: 24 August 2021</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T07:19+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_J4EkbEk">pneumococcal vaccine</term>
					<term xml:id="_222RXat">influenza vaccine</term>
					<term xml:id="_JttD8UG">reminder systems</term>
					<term xml:id="_NArq65d">emergency departments</term>
					<term xml:id="_JKas8qz">cluster-randomized trial</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_AyMDd93"><p xml:id="_3p4meXD"><s xml:id="_5HHrcnv">Objectives.</s><s xml:id="_Pkkca3k">We aimed to evaluate the effectiveness of a multifaceted procedure in improving pneumococcal and influenza vaccinations 6 months after an emergency department (ED) visit among patients aged 65 years and older.</s><s xml:id="_gxPw8f4">Methods.</s><s xml:id="_HhKW8cb">We conducted a cluster-randomized, controlled, parallel-group, open-label implementation trial in 18 EDs in France and Monaco.</s><s xml:id="_8rh7nNu">Participants were recruited from November 2015 to September 2016.</s><s xml:id="_V2sv8VQ">EDs were randomly assigned with a 1:1 ratio to provide either a multifaceted procedure that combined structured information about pneumococcal and influenza vaccines and three text message reminders sent to patients every two weeks (intervention arm) or nonstructured information only (control arm).</s><s xml:id="_KPW4Fw2">The outcomes were selfreported pneumococcal vaccination and influenza vaccination rates within 6 months of enrollment.</s><s xml:id="_qMyYERg">Results.</s><s xml:id="_2zGrkcS">A total of 9 EDs were randomized to the intervention arm (n = 780 patients) and 9 to the control arm (n = 695 patients).</s><s xml:id="_BxaTwR7">The median age for all enrolled patients was 74 years (25-75th</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1." xml:id="_t4xhMAP">Introduction</head><p xml:id="_KPF3r2D"><s xml:id="_hjypMRq">Community-acquired pneumonia and seasonal influenza are major causes of morbimortality worldwide, especially among the elderly and individuals with chronic underlying conditions.</s><s xml:id="_vwmn8st">Influenza and pneumococcal vaccines have been shown to be effective in reducing the risk of influenza occurrence and severity and Streptococcus pneumoniae infections, respectively, in elderly people <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref>.</s><s xml:id="_DXsYaWs">Current international guidelines recommend that all people aged 65 years or older receive influenza vaccination every year <ref type="bibr" target="#b3">[4]</ref> and pneumococcal vaccination with single doses of PCV13 and PPV23 <ref type="bibr" target="#b4">[5]</ref>.</s><s xml:id="_6fDT4XF">In France, seasonal influenza vaccination is recommended annually for people older than 65 years and for younger individuals with chronic underlying diseases.</s><s xml:id="_afWn9vu">Pneumococcal vaccination is recommended on its part for people at risk of invasive pneumococcal infection, i.e., immunocompromised and nonimmunocompromised individuals with an underlying condition, irrespective of their age.</s></p><p xml:id="_ndYVEbz"><s xml:id="_JMTVjrf">Despite the efforts of primary care providers and public health agencies, vaccine coverage has remained far below the expected coverage rate <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>.</s><s xml:id="_pcbvVZF">The most common barriers to vaccination include a perceived lack of safety, a deficit of awareness, complacency (i.e., doubts about the necessity of vaccines), and vaccine misconceptions <ref type="bibr" target="#b7">[8]</ref>.</s><s xml:id="_fAC3uME">To address the growing vaccine hesitancy, a variety of strategies have been implemented and evaluated across countries <ref type="bibr" target="#b8">[9]</ref>.</s><s xml:id="_eXf9Y7V">Most of them are related to the COM-B model for adherence to health recommendations, which assumes that people's capacities, motivations, and opportunities are fundamental factors in the engagement of health-protective behavior <ref type="bibr" target="#b9">[10]</ref>.</s><s xml:id="_Z2aMfpf">Among the most promising interventions based on the COM-B model, those using external cues to action (i.e., circumstances that trigger the decision-making process leading to the uptake of the recommended vaccine, such as advice from a healthcare worker or illness of a friend/relative) seem to be generally effective to address vaccine hesitancy <ref type="bibr" target="#b10">[11]</ref>.</s><s xml:id="_UtDtztR">They include interventions using text messaging systems to promote vaccination in local healthcare facilities and training healthcare providers to improve their vaccine recommendations <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>.</s></p><p xml:id="_R4Uehhr"><s xml:id="_U7sBWHA">Every year, one-third of the population visits hospital emergency departments (EDs) in France.</s><s xml:id="_4FKVKHB">Overall, 10-20% of the adult population makes at least one visit to the ED annually in the United States <ref type="bibr" target="#b13">[14]</ref>.</s><s xml:id="_eEPGRDn">Regardless of the reason for the visit, EDs are a location to assess the general health status of the population; furthermore, a visit to the ED may be an opportunity to initiate interventions to improve patient's adherence to vaccine recommendations.</s></p><p xml:id="_3jUyTJD"><s xml:id="_5xwQyPb">The aim of this study was to determine whether a multifaceted intervention providing patients aged 65 years and older with structured information at the time of ED visit and 3 text message reminders increased pneumococcal and influenza vaccination rates at 6 months of follow-up.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2." xml:id="_6wP4EuX">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1." xml:id="_xteWKWh">Study Design and Setting</head><p xml:id="_t9ZWFUu"><s xml:id="_NvVEpV6">The IMPROVED study is a cluster-randomized, controlled, parallel-group, open-label implementation trial conducted in the ED of 18 acute care hospitals in France and Monaco.</s><s xml:id="_vByhq2G">The rationale and methods for the IMPROVED trial were prespecified and reported in a protocol registered at ClinicalTrials.gov</s><s xml:id="_FxDMuBu">(NCT01899365).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2." xml:id="_hyABfCm">Participants</head><p xml:id="_M7hGszn"><s xml:id="_2WDYVdE">Consecutive patients aged 65 years and older attending EDs from the community or nursing home setting were screened for eligibility on weekdays between November 2015 and September 2016.</s><s xml:id="_mKvjNVm">Participation in the study was proposed after management of the reason for the ED visit was initiated.</s><s xml:id="_tuYtQtN">Participants were enrolled regardless of the reason for ED visit.</s><s xml:id="_MeQfysw">Exclusion criteria included refusal to participate, inability to receive mobile phone text messages, dementia, altered mental status, language restriction, previous pneumococcal vaccination, or contraindication to pneumococcal vaccination.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3." xml:id="_YejcBFG">Randomization</head><p xml:id="_HMBHjUf"><s xml:id="_36DwQdp">Random allocation was performed at the hospital level in order to prevent unintentional spill-over of intervention effects from one study arm to another <ref type="bibr" target="#b14">[15]</ref>.</s><s xml:id="_u8TQmRH">A statistician generated a random allocation sequence, with a 1:1 ratio, and hospitals were matched by university affiliation status, annual number of ED admissions (&lt;40,000 versus ≥40,000), and areas (Paris versus other regions) in order to balance recruitment between study arms.</s><s xml:id="_RzwDUPB">Because the study arm was released at the beginning of the enrollment period, we could not ensure allocation concealment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4." xml:id="_DDZ5wJ4">Study Intervention</head><p xml:id="_wjsTeqn"><s xml:id="_6VwFcsD">Patients randomized in the experimental arm received the multifaceted intervention procedure at the end of the ED visit.</s><s xml:id="_geETGuc">It comprised a brief structured interview with the physician about pneumococcal and influenza burden and the interest of both vaccinations.</s><s xml:id="_HHPC56T">An information sheet with an explanation about the risks and benefits of vaccination and a letter dedicated to the general practitioner stating that the patient was at risk for pneumococcal infection and could benefit from pneumococcal vaccination were given to the patients.</s><s xml:id="_9sUFG5S">Three text messages were sent to patients every 2 weeks to remind them to talk about pneumococcal risk with their general practitioners.</s></p><p xml:id="_NUQgR4g"><s xml:id="_gjRb5Fh">Patients randomized in the control arm received a brief nonstructured interview with the physician about pneumococcal risk and vaccination, an information sheet about the risks and benefits of vaccination, and a letter for their general practitioner stating that the patient was at risk for pneumococcal infection and could benefit from pneumococcal vaccination.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5." xml:id="_8EYhzJc">Blinding</head><p xml:id="_R2NAvhd"><s xml:id="_tW9PKsK">In this open-label trial, patients, care providers, investigators, and outcome assessors were not blinded to allocation.</s><s xml:id="_NNWgj97">Only the statistician was blinded to study arm and hospital until all analyses planned in the statistical analysis plan (SAP) were performed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6." xml:id="_2aeJDpt">Data Collection</head><p xml:id="_MmdhFsf"><s xml:id="_t7pmzeh">Using an electronic case report form, ED physicians prospectively recorded information on baseline patient characteristics, including demographics, reason for ED visit, comorbid conditions, prior history of pneumonia, meningitis or chronic sinusitis, and influenza vaccination status.</s><s xml:id="_XrHPRPj">Patients filled out a questionnaire during the ED visit and were contacted at 6 and 12 months following enrollment for a structured telephone interview with a study clinical research assistant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7." xml:id="_xXV7j9B">Outcomes</head><p xml:id="_VcQfmRz"><s xml:id="_NA2BS25">The primary outcome was self-reported pneumococcal vaccination within 6 months of enrollment.</s><s xml:id="_y5Tsw2a">Secondary outcomes included 6-month self-reported influenza vaccination and 12-month all-cause mortality.</s><s xml:id="_Ud3Xszg">All-cause mortality and date of death were captured by requesting the National Death Index in France (CepiDC) and the city council (DASS) in Monaco.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8." xml:id="_zprnJWh">Sample Size</head><p xml:id="_eqqZHDS"><s xml:id="_cjZgaDz">Assuming a 0.05 intra-cluster correlation coefficient, we estimated that 1800 patients (i.e., 900 patients per study arm) would be required to achieve 80% power for detecting an absolute difference of 15 percentage points in the 6-month pneumococcal vaccination rate between the intervention (35%) and control (20%) study arms in the intention-to-treat analysis, with a two-sided alpha level set at 0.05.</s><s xml:id="_x2jReJK">Anticipating an average number of 100 patients per ED, 18 study sites were required.</s><s xml:id="_BDWjHX3">Because of noncompliance with the recruitment plan, the sponsor and the steering committee decided to stop recruitment on 5 July 2017.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.9." xml:id="_K3uZTt3">Statistical Analysis</head><p xml:id="_MQDKMgg"><s xml:id="_3YGaJsg">The intention-to-treat population consisted of all enrolled patients recorded in the database, with the exception of those who withdrew informed consent.</s><s xml:id="_zCEqCnc">All enrolled patients were analyzed in the study arm to which they were randomly allocated regardless of whether they received the assigned intervention and irrespective of any protocol deviations or violations.</s></p><p xml:id="_2dEBcAb"><s xml:id="_zeUVT4H">Descriptive summary statistics were used for reporting continuous (median and 25th-75th percentiles) and categorical (numbers and percentages) variables.</s><s xml:id="_SThPCs5">We derived odds ratios and absolute difference in 6-month pneumococcal vaccination between study arm point estimates along with the 95% confidence interval (CI) from the logistic regression for the dependent binary variable with the study arm entered as the independent variable.</s><s xml:id="_XDGuqrt">To account for patient clustering within the ED, we used the random intercept model.</s><s xml:id="_JGPayr7">We performed multiple imputations of missing values for the pneumococcal vaccination using multivariate regression with an iterative Markov chain Monte Carlo (MCMC) method.</s><s xml:id="_yJ4vApZ">Fifty imputed data sets were created with a total run length of 50,000 iterations, and imputations were made every 1000 iterations.</s><s xml:id="_79sXAGv">Variables included in the imputation model are listed in Supplementary (Table <ref type="table" target="#tab_0">S1</ref>).</s></p><p xml:id="_mJnn8hz"><s xml:id="_E2nzWbw">To assess the robustness of our findings, we repeated the primary outcome analysis after discarding patients with a missing value for the primary outcome (i.e., casewise analysis) and after restricting the analytical sample to patients who were at risk for invasive pneumococcal infection, i.e., immunocompromised and nonimmunocompromised individuals with an underlying condition for whom pneumococcal vaccination was recommended in France (referred as 'at-risk patients' analysis).</s><s xml:id="_xruehGk">The same approach was applied to compare influenza vaccination and 6-and 12-month all-cause mortality between study arms.</s></p><p xml:id="_j3GP3Hs"><s xml:id="_8nr7vwf">We performed multivariable analysis to assess the effect of imbalances in baseline characteristics between study groups on self-reported 6-month pneumococcal and influenza vaccinations.</s><s xml:id="_yDW9DRc">Odds ratios were adjusted for baseline ED (location in Paris and suburbs, university affiliation, annual volume ≥40,000) and patient (age, gender, enrollment between 1 November and 30 April, reason for ED visit, underlying conditions, history of pneumonia, history of chronic sinusitis, history of meningitis, institution dwelling, history of influenza vaccination, and hospital admission) characteristics.</s></p><p xml:id="_px5YSKr"><s xml:id="_vAbgPfF">Two-tailed values of p &gt; 0.05 were considered statistically significant.</s><s xml:id="_yqsrKHw">All statistical analyses were conducted using Stata 14.0 Special Edition (StataCorp, College Station, TX, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.10." xml:id="_YhRXT74">Ethics and Regulatory Issues</head><p xml:id="_NZdfZy9"><s xml:id="_zqBCznA">This study complied with the Declaration of Helsinki for research involving human subjects.</s><s xml:id="_eACvHq2">An institutional review board (Comité de Protection des Personnes Ile de France 1, IRB 00008522, 2014-janvier-13467), the French Data Protection Authority (Commission nationale de l'informatique et des libertés) (DR-2015-108), and ANSM (IDRCB: 2013-A00943-42) reviewed and approved the study protocol and the consent form prior to study initiation.</s><s xml:id="_4YqATeH">All participants provided informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3." xml:id="_R6tsdJs">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1." xml:id="_xkdbmRh">Study Population</head><p xml:id="_kaaanHG"><s xml:id="_u89Gy4X">Of 20 emergency departments invited to participate, 2 declined, and 18 were randomized (9 in the experimental arm and 9 in the control arm, Figure <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_G3zJyUS">Between 9 November 2015 and 5 July 2017, 1475 patients (780 in the intervention arm and 695 in the control arm) were enrolled (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_yzkCbJv">The median number of patients enrolled in each emergency department was 98 (range: 18 to 145) (Table <ref type="table" target="#tab_1">S2</ref>).</s></p><p xml:id="_9d5EctM"><s xml:id="_FGhbbt8">Two-tailed values of p &gt; 0.05 were considered statistically significant.</s><s xml:id="_WP8xbKW">All statistical analyses were conducted using Stata 14.0 Special Edition (StataCorp, College Station, TX, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.10." xml:id="_MGwz5x9">Ethics and Regulatory Issues</head><p xml:id="_fAkdK7B"><s xml:id="_mxQaGXZ">This study complied with the Declaration of Helsinki for research involving human subjects.</s><s xml:id="_myWvcHx">An institutional review board (Comité de Protection des Personnes Ile de France 1, IRB 00008522, 2014-janvier-13467), the French Data Protection Authority (Commission nationale de l'informatique et des libertés) (DR-2015-108), and ANSM (IDRCB: 2013-A00943-42) reviewed and approved the study protocol and the consent form prior to study initiation.</s><s xml:id="_Fgg2tbF">All participants provided informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3." xml:id="_RhFwBVB">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1." xml:id="_7EAGfgN">Study Population</head><p xml:id="_BCXnm4j"><s xml:id="_SnkZGGy">Of 20 emergency departments invited to participate, 2 declined, and 18 were randomized (9 in the experimental arm and 9 in the control arm, Figure <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_yUKPABK">Between 9 November 2015 and 5 July 2017, 1475 patients (780 in the intervention arm and 695 in the control arm) were enrolled (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_qp8r4Cs">The median number of patients enrolled in each emergency department was 98 (range: 18 to 145) (Table <ref type="table" target="#tab_1">S2</ref>).</s><s xml:id="_VQjmeA4">The median age for all enrolled patients was 74 years (25-75th percentiles, 69 to 82): 50.1% were male, 34.9% had at least one underlying condition, and 30.7% were at risk for The median age for all enrolled patients was 74 years (25-75th percentiles, 69 to 82): 50.1% were male, 34.9% had at least one underlying condition, and 30.7% were at risk for invasive pneumococcal infection (Table <ref type="table" target="#tab_0">1</ref>).</s><s xml:id="_8EdAEU7">The two study arms were well balanced with respect to baseline characteristics, with the exception of age, reasons for ED visit, history of chronic sinusitis, and chronic respiratory diseases.</s><s xml:id="_vg3CdE8">Patients assigned to the intervention arm were less likely to be enrolled between 1 November and 30 April (Figure <ref type="figure" target="#fig_1">S1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2." xml:id="_RauKdXV">Self-Reported Pneumococcal Vaccination</head><p xml:id="_qGjS2Tz"><s xml:id="_a6844dd">Information on self-reported pneumococcal vaccination was available for 1003 patients (549 (70.3%) in the intervention arm and 454 (65.3%) in the control arm; p = 0.04).</s><s xml:id="_nSDRYN4">Missing values for the primary outcome were imputed for 87 patients who died within 6 months (44 (5.6%) in the intervention arm and 43 (6.2%) in the control arm; p = 0.66), 275 who were lost to follow-up at 6 months (133 (17.0%) in the intervention arm and 142 (20.4%) in the control arm; p = 0.10), and 110 who did not answer (54 6.9%) in the intervention arm and 56 8.1%) in the control arm; p = 0.14) (Table <ref type="table" target="#tab_1">2</ref>).</s><s xml:id="_hEnMGEJ">The estimated percentages of pneumococcal vaccination were 6.4% and 4.6% in the intervention and control arms, respectively (absolute difference: 1.8 percentage points; 95% CI: -0.9 to 4.4; p = 0.19) (Table <ref type="table" target="#tab_2">3</ref>).</s><s xml:id="_cBR8fGU">Results from casewise and 'at-risk patients' analyses were rather similar (Tables <ref type="table" target="#tab_2">S3</ref> and <ref type="table">S4</ref>).</s><s xml:id="_b5tyjbE">In univariable analysis, baseline characteristics associated with self-reported pneumococcal vaccination included ED visit for respiratory tract infection, underlying immunosuppression, history of chronic sinusitis, and recent history of influenza vaccination (Table <ref type="table">S5</ref>).</s><s xml:id="_t3NdJES">After adjusting for baseline characteristics, no significant association was observed between the intervention arm and self-reported pneumococcal vaccination (Table <ref type="table">S6</ref>).</s><s xml:id="_6JaEcqx">Abbreviations: CI = confidence interval.</s><s xml:id="_7m924eS">* Odds ratio and absolute difference point estimates along with 95% confidence intervals were derived from logistic regression for the dependent binary variable with the study arm entered as the independent variable.</s><s xml:id="_7NcJ2VQ">To account for patient clustering within ED, we used a random intercept model.</s><s xml:id="_cvXFMrp">Missing values for self-reported pneumococcal and influenza vaccination were replaced by multiple imputation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3." xml:id="_6Xa6D9z">Self-Reported Influenza Vaccination</head><p xml:id="_MJ2CWxU"><s xml:id="_9KwUsdN">The secondary outcome of self-reported influenza vaccination was available in 873 patients (474 60.8%) in the intervention arm and 399 (57.4%)) in the control arm; p = 0.19) (Table <ref type="table" target="#tab_1">2</ref>).</s><s xml:id="_g7btCKn">The estimated percentages of influenza vaccination were 52.1% and 40.0% in the intervention and control arms, respectively (absolute difference: 12.1 percentage points; 95% CI: 2.4 to 21.8; p = 0.01) (Table <ref type="table" target="#tab_2">3</ref>).</s><s xml:id="_t6KX5GG">Estimates were unchanged in casewise analysis (Table <ref type="table" target="#tab_2">S3</ref>)).</s><s xml:id="_wnKX4Bd">In univariable analysis, baseline characteristics associated with self-reported influenza vaccination included advancing age, female gender, history of stroke, and previous history of influenza vaccination (Table <ref type="table">S7</ref>).</s><s xml:id="_kT5xrQ4">After adjusting for baseline characteristics, the intervention arm remained significantly associated with an increased odds ratio of self-reported influenza vaccination (Table <ref type="table">S6</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4." xml:id="_NZ4Fbcy">6-Month and 12-Month All-Cause Mortality</head><p xml:id="_xA635fA"><s xml:id="_TZ3TcyW">All-cause mortality did not differ between the intervention and control arms at 6 months (absolute difference: -0.5 percentage points: 95% CI: -3.0 to 1.9; p = 0.66) and 12 months of enrollment (absolute difference: -1.4 percentage points; 95% CI: -6.1 to 3.2; p = 0.54) (Table <ref type="table" target="#tab_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4." xml:id="_Nfb5P8Y">Discussion</head><p xml:id="_ykYTE6T"><s xml:id="_tZuYap8">In this cluster-randomized, controlled, parallel-group, open-label, implementation trial, provision of information during ED visit followed by reminders through text messages did not alter 6-month pneumococcal vaccination but was associated with significant improvement in influenza vaccination rate among patients aged 65 years and older.</s></p><p xml:id="_bfrWadc"><s xml:id="_pJwGpDm">To enhance the generalizability of our results, we enrolled consecutive patients attending EDs during the daytime, thanks to dedicated research staff in each study site.</s></p><p xml:id="_uBD2FYH"><s xml:id="_HUu5Uk3">All patients aged 65 years and older were eligible to participate, regardless of the reason for admission to ED, except those already vaccinated against S. pneumoniae.</s><s xml:id="_hvdgPgG">We enrolled patients visiting hospitals located in different areas in France and Monaco with a large population pool in both tertiary and nontertiary centers.</s><s xml:id="_Nzss4ur">Our study population was representative of elderly patients presenting to the ED in France, with regard to medical reasons for ED visit and subsequent hospital admission rate <ref type="bibr" target="#b15">[16]</ref>.</s><s xml:id="_YMh9vCJ">At baseline, 50.1% of participants reported influenza vaccination coverage for the current season, which was close to the French national estimates ranging from 46% to 48% during the 2015-2017 period, for people older than 65 years old <ref type="bibr" target="#b16">[17]</ref>.</s><s xml:id="_5xdSpfB">These observations make us believe that the results of our trial can be extrapolated to other French EDs.</s></p><p xml:id="_29gcQKY"><s xml:id="_RsC2gGw">Current international guidelines recommend that individuals aged 65 years or older receive annual influenza vaccination and pneumococcal vaccination every five years <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s xml:id="_95YNqY3">In France, this is also the case for seasonal influenza vaccination, whereas pneumococcal vaccination is restricted to people at risk for invasive pneumococcal infection.</s><s xml:id="_TUHCtFs">Although age above 65 years is not per se considered as an indication for pneumococcal vaccination in France, pneumococcal vaccines had a marketing authorization for all adults above 65 years of age because the overall incidence of pneumococcal disease rises greatly in this age group <ref type="bibr" target="#b17">[18]</ref>.</s><s xml:id="_w5uQkT6">Results of the analysis restricted to the 'at-risk' subgroup for which pneumococcal vaccination is recommended were consistent with those for the overall study population.</s></p><p xml:id="_uTXsqEZ"><s xml:id="_Xk5tuZb">Our study was conducted in the setting of the ED.</s><s xml:id="_S4Y44rh">There are on average 21 million ED visits per year over the last decade <ref type="bibr" target="#b15">[16]</ref>.</s><s xml:id="_baG2ubu">Of those, around 20% involve adults aged 75 or more <ref type="bibr" target="#b18">[19]</ref>.</s><s xml:id="_UPB4gRb">Previous studies have reported that up to 69% and 45% of patients visiting the ED were at high risk for influenza or pneumococcal disease, respectively, although less than 20% of that high-risk population were vaccinated <ref type="bibr" target="#b13">[14]</ref>.</s><s xml:id="_g4r7atx">It should be noted that patients usually visit the ED for acute medical conditions requiring curative care and can be reluctant to vaccinate in the ED, as this is not the main reason for ED visit.</s><s xml:id="_9f5dXQG">Patients refer to their general practitioner for health prevention.</s><s xml:id="_BkPhXn8">To note, emergency physicians daily vaccinate many patients against tetanus but do not offer influenza and pneumococcal vaccinations <ref type="bibr" target="#b19">[20]</ref>.</s><s xml:id="_XaBdNs7">However, they can easily enroll patients in intervention programs that provide reminders and identify local sources of vaccines, without increased staffing.</s></p><p xml:id="_gPprhH7"><s xml:id="_XPNwQC3">A recent cluster-randomized crossover trial, conducted in primary care in Singapore, showed that point-of-care informational interventions (i.e., flyers and posters) contributed to increased influenza and pneumococcal vaccination uptake <ref type="bibr" target="#b20">[21]</ref>.</s><s xml:id="_grbZggu">Numerous studies showed that patient reminder and recall systems improved immunization rates in various types of settings, based on moderate certainty evidence <ref type="bibr" target="#b21">[22]</ref>, but few of them focused on text message interventions.</s><s xml:id="_7gy8B9y">Herrett et al. <ref type="bibr" target="#b22">[23]</ref> and Regan et al. <ref type="bibr" target="#b23">[24]</ref> found a modest improvement in influenza vaccine uptake among at-risk groups in the United Kingdom and Australia.</s><s xml:id="_xA6FQ9H">In the USA, a patient-level randomized controlled trial was implemented in a low-income population and showed that text messages sent to parents were associated with a 9% relative increase in influenza vaccine uptake among children <ref type="bibr" target="#b12">[13]</ref>.</s><s xml:id="_prd75dg">Although people across all age groups communicate via text messaging, further research is still needed to investigate the effectiveness of this mode of communication on vaccination uptake among seniors <ref type="bibr" target="#b10">[11]</ref>.</s></p><p xml:id="_GtnZExg"><s xml:id="_CjuXYye">Our multifaceted intervention procedure based on external cues to action combined structured oral interviews, written information, and text messages as reminders.</s><s xml:id="_Z9n63Hb">Although our study intervention combined different components that were more resource and time consuming than text message reminders, we did not find evidence of effectiveness on pneumococcal vaccination uptake.</s><s xml:id="_WsKdXYG">There are several potential explanations for these negative findings.</s><s xml:id="_w6NySAg">First, our intervention might have been hampered by the tension in the supply of pneumococcal vaccines (PPV23), leading even to the point of stock-outs in pharmacies at the end of 2017, in France.</s><s xml:id="_gNWTCAy">Second, our intervention might have been attenuated by French guidelines advocating pneumococcal vaccination for at-risk patients but our findings were rather comparable in the 'at-risk' population.</s><s xml:id="_H7juBPV">Interestingly, our multifaceted intervention significantly increased influenza vaccination uptake whereas half of the participants reported being previously vaccinated against influenza.</s><s xml:id="_xPtK354">We previously found that history of seasonal influenza vaccination was associated with willingness to be vaccinated <ref type="bibr" target="#b24">[25]</ref>.</s><s xml:id="_9P2ftHh">Participants in our study were not previously vaccinated against pneumococcal and therefore might be less prone to vaccination.</s><s xml:id="_ks9ABPq">Second, awareness of the pneumococcal vaccination recommendation is probably lower among both physicians and patients than for influenza vaccine <ref type="bibr" target="#b25">[26]</ref>.</s><s xml:id="_58hY55p">Seasonal influenza vaccination is well publicized across all age groups promoted by campaigns and health professionals and in workplaces, whereas pneumococcal vaccination appears to have a much lower promotion <ref type="bibr" target="#b26">[27]</ref>.</s><s xml:id="_vMDZJjH">Patients aged 65 years and older receive a voucher from the French national health insurance to be vaccinated against influenza, whereas this is not the case for pneumococcus vaccine.</s><s xml:id="_n9PdTHb">Finally, the content of the message contributes to the success of interventions.</s><s xml:id="_G4bSXDN">It is possible that there may have been a misunderstanding between influenza infection and the risk-related pulmonary complications and pneumococcal infection itself.</s></p><p xml:id="_phHECc7"><s xml:id="_XjXdVPz">We acknowledge several limitations to our study.</s><s xml:id="_Mhfqprb">First, vaccine uptake was selfreported and not verified by vaccination booklets or medical records.</s><s xml:id="_3sp2YVt">Second, no data were available on the proportion of patients who effectively received or read the text messages.</s><s xml:id="_G9hXGR7">Third, an imbalance was observed in baseline patient characteristics in this cluster-randomized trial.</s><s xml:id="_ntSwPCe">Although the results were unchanged in multivariable analysis, we cannot exclude residual confounding by an imbalance in unmeasured characteristics.</s><s xml:id="_M3VKRaP">Fourth, heterogeneity in participation rates across study sites could not be investigated because this information was not recorded in this trial.</s><s xml:id="_DjBEycV">Fifth, external factors may have hampered pneumococcal vaccination, such as the tension in the supply of pneumococcal vaccines in France.</s><s xml:id="_hUTPWSZ">Sixth, because of noncompliance with the recruitment plan, the study had to be stopped prematurely before reaching the required number of subjects.</s></p><p xml:id="_6rdWXr6"><s xml:id="_MR7FyQ4">To conclude, a multifaceted intervention delivered in the ED increased influenza vaccination coverage but had no significant effect on pneumococcal vaccination coverage among elderly patients 6 months after ED visit.</s><s xml:id="_RRAuD4X">Whatever the reason for visiting hospital EDs, it can be an opportunity to educate patients about the importance of vaccinations and to implement automated reminder systems.</s><s xml:id="_U7SKkQ2">However, the heterogeneity in effectiveness between the two vaccinations shows the complexity of receiving this message when it comes to diseases that receive little media coverage and are therefore not well known by patients.</s><s xml:id="_tp5tJ2C">Efforts are warranted to provide better information on pneumococcal diseases and the benefits of antipneumococcal vaccine, especially in the elderly.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p xml:id="_YczgFs9"><s xml:id="_MV2JmUd">Consort flow diagram, IMPROVED trial.</s><s xml:id="_svW4MED">ED = emergency department</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc><div><p xml:id="_EBdMD4V"><s xml:id="_wvqqjVw">Figure 1.</s><s xml:id="_KpwvqV4">Consort flow diagram, IMPROVED trial.</s><s xml:id="_aajjrfZ">ED = emergency department.</s></p></div></figDesc><graphic coords="5,42.20,298.29,513.21,380.57" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_x2Ya5x6"><s xml:id="_akYV5sp">Comparison of baseline patient characteristics between study arms; IMPROVED trial.</s></p></div></figDesc><table><row><cell>Baseline Characteristics</cell><cell cols="2">All (n = 1475) n or med (% or IQR)</cell><cell cols="2">Intervention (n = 780) n or med (% or IQR)</cell><cell cols="2">Control (n = 695) n or med (% or IQR)</cell><cell>p-Value</cell></row><row><cell>Age (year)</cell><cell>74</cell><cell>(69-82)</cell><cell>74</cell><cell>(68-80)</cell><cell>76</cell><cell>(69-83)</cell><cell>&lt;0.001</cell></row><row><cell>Male gender</cell><cell>739</cell><cell>(50.1)</cell><cell>389</cell><cell>(49.9)</cell><cell>350</cell><cell>(50.4)</cell><cell>0.85</cell></row><row><cell>Study site</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Location in Paris and suburbs</cell><cell>517</cell><cell>(35.1)</cell><cell>300</cell><cell>(38.5)</cell><cell>217</cell><cell>(31.2)</cell><cell>0.004</cell></row><row><cell>University hospital</cell><cell>874</cell><cell>(59.3)</cell><cell>499</cell><cell>(64.0)</cell><cell>375</cell><cell>(54.0)</cell><cell>&lt;0.001</cell></row><row><cell>ED annual volume ≥ 40,000</cell><cell>916</cell><cell>(62.1)</cell><cell>499</cell><cell>(64.0)</cell><cell>417</cell><cell>(60.0)</cell><cell>0.12</cell></row><row><cell>Enrolled between Nov. and Apr.</cell><cell>865</cell><cell>(58.6)</cell><cell>371</cell><cell>(47.6)</cell><cell>494</cell><cell>(71.1)</cell><cell>&lt;0.001</cell></row><row><cell>Reason for ED visit</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.002</cell></row><row><cell>Respiratory tract infection</cell><cell>93</cell><cell>(6.3)</cell><cell>41</cell><cell>(5.3)</cell><cell>52</cell><cell>(7.5)</cell><cell></cell></row><row><cell>Nonrespiratory tract infection</cell><cell>42</cell><cell>(2.8)</cell><cell>20</cell><cell>(2.6)</cell><cell>22</cell><cell>(3.2)</cell><cell></cell></row><row><cell>Medical reason</cell><cell>934</cell><cell>(63.3)</cell><cell>525</cell><cell>(67.3)</cell><cell>409</cell><cell>(58.8)</cell><cell></cell></row><row><cell>Traumatic reason</cell><cell>291</cell><cell>(19.7)</cell><cell>151</cell><cell>(19.4)</cell><cell>140</cell><cell>(20.1)</cell><cell></cell></row><row><cell>Nontraumatic surgery</cell><cell>23</cell><cell>(1.6)</cell><cell>9</cell><cell>(1.1)</cell><cell>14</cell><cell>(2.0)</cell><cell></cell></row><row><cell>Psychiatry</cell><cell>7</cell><cell>(0.5)</cell><cell>4</cell><cell>(0.5)</cell><cell>3</cell><cell>(0.4)</cell><cell></cell></row><row><cell>Other</cell><cell>85</cell><cell>(5.8)</cell><cell>30</cell><cell>(3.8)</cell><cell>55</cell><cell>(7.9)</cell><cell></cell></row><row><cell>Medical history</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>At least one underlying condition</cell><cell>515</cell><cell>(34.9)</cell><cell>271</cell><cell>(34.7)</cell><cell>244</cell><cell>(35.1)</cell><cell>0.88</cell></row><row><cell>Chronic respiratory disease</cell><cell>96</cell><cell>(6.5)</cell><cell>37</cell><cell>(4.7)</cell><cell>59</cell><cell>(8.5)</cell><cell>0.004</cell></row><row><cell>Heart failure</cell><cell>209</cell><cell>(14.2)</cell><cell>119</cell><cell>(15.3)</cell><cell>90</cell><cell>(12.9)</cell><cell>0.20</cell></row><row><cell>Immunosuppression</cell><cell>17</cell><cell>(1.1)</cell><cell>7</cell><cell>(0.9)</cell><cell>10</cell><cell>(1.4)</cell><cell>0.33</cell></row><row><cell>History of stroke</cell><cell>97</cell><cell>(6.6)</cell><cell>48</cell><cell>(6.1)</cell><cell>49</cell><cell>(7.0)</cell><cell>0.49</cell></row><row><cell>Chronic renal failure</cell><cell>70</cell><cell>(4.7)</cell><cell>30</cell><cell>(3.8)</cell><cell>40</cell><cell>(5.8)</cell><cell>0.08</cell></row><row><cell>Cirrhosis</cell><cell>17</cell><cell>(1.1)</cell><cell>10</cell><cell>(1.3)</cell><cell>7</cell><cell>(1.0)</cell><cell>0.62</cell></row><row><cell>Cancer</cell><cell>137</cell><cell>(9.3)</cell><cell>83</cell><cell>(10.6)</cell><cell>54</cell><cell>(7.8)</cell><cell>0.06</cell></row><row><cell>History of pneumonia</cell><cell>87</cell><cell>(5.9)</cell><cell>47</cell><cell>(6.0)</cell><cell>40</cell><cell>(5.8)</cell><cell>0.83</cell></row><row><cell>History of meningitis</cell><cell>9</cell><cell>(0.6)</cell><cell>5</cell><cell>(0.6)</cell><cell>4</cell><cell>(0.6)</cell><cell>&gt;0.999</cell></row><row><cell>History of chronic sinusitis</cell><cell>41</cell><cell>(2.8)</cell><cell>31</cell><cell>(4.0)</cell><cell>10</cell><cell>(1.4)</cell><cell>0.003</cell></row><row><cell>Institution dwelling</cell><cell>19</cell><cell>(1.3)</cell><cell>10</cell><cell>(1.3)</cell><cell>9</cell><cell>(1.3)</cell><cell>&gt;0.999</cell></row><row><cell>History of influenza vaccination</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.26</cell></row><row><cell>Current season influenza vaccination</cell><cell>739</cell><cell>(50.1)</cell><cell>387</cell><cell>(49.6)</cell><cell>352</cell><cell>(50.6)</cell><cell></cell></row><row><cell>influenza vaccination &gt; 1 year</cell><cell>240</cell><cell>(16.3)</cell><cell>134</cell><cell>(17.2)</cell><cell>106</cell><cell>(15.2)</cell><cell></cell></row><row><cell>No history of influenza vaccination</cell><cell>493</cell><cell>(33.4)</cell><cell>259</cell><cell>(33.2)</cell><cell>234</cell><cell>(33.7)</cell><cell></cell></row><row><cell>Missing data</cell><cell>3</cell><cell>(0.2)</cell><cell>0</cell><cell>(0.0)</cell><cell>3</cell><cell>(0.4)</cell><cell></cell></row><row><cell>At risk of invasive pneumococcal infection *</cell><cell>453</cell><cell>(30.7)</cell><cell>241</cell><cell>(30.9)</cell><cell>212</cell><cell>(30.5)</cell><cell>0.87</cell></row><row><cell>Hospitalization</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.91</cell></row><row><cell>Yes</cell><cell>766</cell><cell>(51.9)</cell><cell>409</cell><cell>(52.4)</cell><cell>357</cell><cell>(51.4)</cell><cell></cell></row><row><cell>No</cell><cell>702</cell><cell>(47.6)</cell><cell>367</cell><cell>(47.0)</cell><cell>335</cell><cell>(48.2)</cell><cell></cell></row><row><cell>Missing data</cell><cell>7</cell><cell>(0.5)</cell><cell>4</cell><cell>(0.5)</cell><cell>3</cell><cell>(0.4)</cell><cell></cell></row></table><note xml:id="_83Dgy5A"><p><s xml:id="_nyeXU38">Abbreviations: ED = emergency department.</s><s xml:id="_hcGessu">* including immune suppression, sickle cell disease, active cancer, congestive heart failure, chronic respiratory disease, renal disease, cirrhosis, and history of meningitis.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p xml:id="_5fPbVav"><s xml:id="_TYTmz6e">Comparison of 6-month and 12-month outcomes between study arms; IMPROVED trial.</s></p></div></figDesc><table><row><cell>Outcomes</cell><cell cols="2">All (n = 1475) n (%)</cell><cell cols="2">Intervention (n = 780) n (%)</cell><cell cols="2">Control (n = 695) n (%)</cell><cell>p-Value</cell></row><row><cell>6-month outcomes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Lost to follow-up</cell><cell>275</cell><cell>(18.6)</cell><cell>133</cell><cell>(17.0)</cell><cell>142</cell><cell>(20.4)</cell><cell>0.10</cell></row><row><cell>Death</cell><cell>87</cell><cell>(5.9)</cell><cell>44</cell><cell>(5.6)</cell><cell>43</cell><cell>(6.2)</cell><cell>0.66</cell></row><row><cell>Self-reported pneumococcal vaccination</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.14</cell></row><row><cell>Yes</cell><cell>62</cell><cell>(4.2)</cell><cell>38</cell><cell>(4.9)</cell><cell>24</cell><cell>(3.4)</cell><cell></cell></row><row><cell>No</cell><cell>941</cell><cell>(63.8)</cell><cell>511</cell><cell>(65.5)</cell><cell>430</cell><cell>(61.9)</cell><cell></cell></row><row><cell>No response</cell><cell>110</cell><cell>(7.5)</cell><cell>54</cell><cell>(6.9)</cell><cell>56</cell><cell>(8.1)</cell><cell></cell></row><row><cell>Not specified (death or lost to follow-up)</cell><cell>362</cell><cell>(24.5)</cell><cell>177</cell><cell>(22.7)</cell><cell>185</cell><cell>(26.6)</cell><cell></cell></row><row><cell>Self-reported influenza vaccination</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>&lt;0.001</cell></row><row><cell>Yes</cell><cell>387</cell><cell>(26.2)</cell><cell>239</cell><cell>(30.6)</cell><cell>148</cell><cell>(21.3)</cell><cell></cell></row><row><cell>No</cell><cell>486</cell><cell>(32.9)</cell><cell>235</cell><cell>(30.1)</cell><cell>251</cell><cell>(36.1)</cell><cell></cell></row><row><cell>No response</cell><cell>240</cell><cell>(16.3)</cell><cell>129</cell><cell>(16.5)</cell><cell>111</cell><cell>(16.0)</cell><cell></cell></row><row><cell>Not specified (death or lost to follow-up)</cell><cell>362</cell><cell>(24.5)</cell><cell>177</cell><cell>(22.7)</cell><cell>185</cell><cell>(26.6)</cell><cell></cell></row><row><cell>12-month outcome</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Death</cell><cell>154</cell><cell>(10.4)</cell><cell>76</cell><cell>(9.7)</cell><cell>78</cell><cell>(11.2)</cell><cell>0.35</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc><div><p xml:id="_6AD7KVb"><s xml:id="_XYSgTSY">Comparison of primary and secondary outcomes in intention-to-treat analysis; IMPROVED trial (N = 1475).</s></p></div></figDesc><table><row><cell>Outcome</cell><cell>Intervention (n = 780)</cell><cell>Control (n = 695)</cell><cell cols="2">Odds Ratio * (95% CI)</cell><cell cols="2">Absolute Difference * (95% CI)</cell><cell>p-Value</cell></row><row><cell>Self-reported 6-month pneumococcal vaccination; %</cell><cell>6.4</cell><cell>4.6</cell><cell>1.41</cell><cell>(0.84 to 2.37)</cell><cell>1.8</cell><cell>(-0.9 to 4.4)</cell><cell>0.19</cell></row><row><cell>Self-reported 6-month influenza vaccination, %</cell><cell>52.1</cell><cell>40.0</cell><cell>1.63</cell><cell>(1.10 to 2.42)</cell><cell>12.1</cell><cell>(2.4 to 21.8)</cell><cell>0.01</cell></row><row><cell>6-month all-cause mortality, %</cell><cell>5.6</cell><cell>6.2</cell><cell>0.91</cell><cell>(0.59 to 1.40)</cell><cell>-0.5</cell><cell>(-3.0 to 1.9)</cell><cell>0.66</cell></row><row><cell>12-month all-cause mortality, %</cell><cell>9.0</cell><cell>10.5</cell><cell>0.85</cell><cell>(0.50 to 1.43)</cell><cell>-1.4</cell><cell>(-6.1 to 3.2)</cell><cell>0.54</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_2Qdanqt">Acknowledgments:</head><p xml:id="_YeMEK6A"><s xml:id="_HUBH4wF">We are indebted to <rs type="person">Mélody Nicolaï</rs>, <rs type="person">Céline Dugourd</rs>, and <rs type="person">Nicolas Rijo</rs> (<rs type="affiliation">unité de recherche Clinique, Centre Hospitalier Princesse Grace, Monaco</rs>) for fixing regulatory issues and practical details and for providing patients' follow-up.</s><s xml:id="_XKFdAjf">We also want to thank <rs type="person">Dr Hervé Raps</rs> and <rs type="person">Pr Patrick Rampal</rs>, <rs type="affiliation">Centre Scientifique de Monaco</rs>, for constant support.</s><s xml:id="_u8THM2R">Finally, we acknowledge patients who accepted to participate in the study.</s></p></div>
			</div>			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8eKa5qE">Supplementary Materials:</head><p xml:id="_b3BSyfE"><s xml:id="_QjQgHUU">The following are available online at <ref type="url" target="https://www.mdpi.com/article/10.3390/vaccines9090962/s1">https://www.mdpi.com/article/10  .3390/vaccines9090962/s1</ref>, Figure <ref type="figure">S1</ref>: Numbers of patients enrolled per month in the intervention and control groups, IMPROVED trial, Table <ref type="table">S1</ref>: Variables entered in the multivariate imputation model, IMPROVED trial, Table <ref type="table">S2</ref>: Characteristics of Emergency Departments participating in the IMPROVED trial, Table <ref type="table">S3</ref>: Comparison of primary and secondary outcomes in casewise analysis; IM-PROVED trial, Table <ref type="table">S4</ref>: Comparison of primary and secondary outcomes restricted to the subgroup of 'at risk' patients in intention-to-treat analysis; IMPROVED trial, Table <ref type="table">S5</ref>: Comparison of baseline characteristics according to self-reported 6-month pneumococcal vaccination; IMPROVED trial, Table <ref type="table">S6</ref>: Adjusted odds ratio of self-reported pneumococcal and influenza vaccination associated with intervention arm in intention-to-treat analysis; IMPROVED trial (N = 1475), Table <ref type="table">S7</ref>: Comparison of baseline patient characteristics according to self-reported 6-month influenza vaccination; IMPROVED trial.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_VqrervB">Author</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_Zt29JGr">Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Falkenhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Remschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Harder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hummers-Pradier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Wichmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bogdan</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0169368</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FHNdSmQ">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">169368</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Falkenhorst, G.; Remschmidt, C.; Harder, T.; Hummers-Pradier, E.; Wichmann, O.; Bogdan, C. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta- Analysis. PLoS ONE 2017, 12, e0169368. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_Hx3URj9">Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bonten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Huijts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bolkenbaas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Webber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Van Werkhoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Van Deursen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Verheij</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa1408544</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4z8d2uH">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="1114" to="1125" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bonten, M.J.; Huijts, S.M.; Bolkenbaas, M.; Webber, C.; Patterson, S.; Gault, S.; van Werkhoven, C.H.; Van Deursen, A.M.; Sanders, E.A.; Verheij, T.J.; et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N. Engl. J. Med. 2015, 372, 1114-1125. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_uTXyBny">Vaccines for preventing influenza in the elderly</title>
		<author>
			<persName><forename type="first">V</forename><surname>Demicheli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jefferson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Di Pietrantonj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ferroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Thorning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rivetti</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd004876.pub4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rTnsjyu">Cochrane Database Syst. Rev</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">4876</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Demicheli, V.; Jefferson, T.; Di Pietrantonj, C.; Ferroni, E.; Thorning, S.; Thomas, R.E.; Rivetti, A. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev. 2018, 2, CD004876. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_Fb4BrNG">Vaccines against influenza WHO position paper-November 2012</title>
		<idno type="DOI">10.1016/j.vaccine.2012.04.093</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rHt6SE8">Relev. Epidemiol. Hebd</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="461" to="476" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vaccines against influenza WHO position paper-November 2012. Relev. Epidemiol. Hebd. 2012, 87, 461-476.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_EBq3TYq">Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tomczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stoecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gierke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Whitney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hadler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pilishvili</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dhbQ74E">MMWR Morb. Mortal. Wkly. Rep</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="822" to="825" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tomczyk, S.; Bennett, N.M.; Stoecker, C.; Gierke, R.; Moore, M.R.; Whitney, C.G.; Hadler, S.; Pilishvili, T. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recom- mendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 2014, 63, 822-825. [PubMed]</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_FKCTrcJ">Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vietri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Harnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Emir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chilson</surname></persName>
		</author>
		<idno type="DOI">10.1080/21645515.2019.1632683</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_x2aSTgk">Hum. Vaccines Immunother</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="161" to="168" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vietri, J.; Harnett, J.; Emir, B.; Chilson, E. Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions. Hum. Vaccines Immunother. 2020, 16, 161-168. [CrossRef] [PubMed]</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_DM4hr4T">Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kopp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Mangin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gantzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lekens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Simoneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ravelomanantsoa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-F</forename><surname>Bergmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sellier</surname></persName>
		</author>
		<idno type="DOI">10.1080/21645515.2020.1756669</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cpJEaAt">Hum. Vaccines Immunother</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="162" to="169" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kopp, A.; Mangin, O.; Gantzer, L.; Lekens, B.; Simoneau, G.; Ravelomanantsoa, M.; Evans, J.; Bergmann, J.-F.; Sellier, P. Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease. Hum. Vaccines Immunother. 2021, 17, 162-169. [CrossRef] [PubMed]</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_NYXtYDE">Does correcting myths about the flu vaccine work? An experimental evaluation of the effects of corrective information</title>
		<author>
			<persName><forename type="first">B</forename><surname>Nyhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Reifler</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2014.11.017</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FAD5BUN">Vaccine</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="459" to="464" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nyhan, B.; Reifler, J. Does correcting myths about the flu vaccine work? An experimental evaluation of the effects of corrective information. Vaccine 2015, 33, 459-464. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_BAGBDQG">Strategies for addressing vaccine hesitancy-A systematic review</title>
		<author>
			<persName><forename type="first">C</forename><surname>Jarrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>O'leary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Eckersberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Larson</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2015.04.040</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4c7F229">Vaccine</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="4180" to="4190" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jarrett, C.; Wilson, R.; O&apos;Leary, M.; Eckersberger, E.; Larson, H.J. Strategies for addressing vaccine hesitancy-A systematic review. Vaccine 2015, 33, 4180-4190. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_xgyp7Q6">Understanding vaccine acceptance and demand-and ways to increase them</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Habersaat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jackson</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00103-019-03063-0</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mXf2hsQ">Bundesgesundheitsblatt Gesundh. Gesundh</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="32" to="39" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Habersaat, K.B.; Jackson, C. Understanding vaccine acceptance and demand-and ways to increase them. Bundesgesundheitsblatt Gesundh. Gesundh. 2019, 63, 32-39. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_KTbAUq6">Interventions to increase influenza vaccination rates of those 60 years and older in the community</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Lorenzetti</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd005188.pub4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_B9W7nJ5">Cochrane Database Syst. Rev</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">5188</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thomas, R.E.; Lorenzetti, D.L. Interventions to increase influenza vaccination rates of those 60 years and older in the community. Cochrane Database Syst. Rev. 2018, 5, CD005188. [CrossRef] [PubMed]</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_SWGBHpE">Announcements Versus Conversations to Improve HPV Vaccination Coverage: A Randomized Trial</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">T</forename><surname>Brewer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Malo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Gilkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lathren</surname></persName>
		</author>
		<idno type="DOI">10.1542/peds.2016-1764</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_C9QEwkH">Pediatrics</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page">20161764</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brewer, N.T.; Hall, M.E.; Malo, T.; Gilkey, M.B.; Quinn, B.; Lathren, C. Announcements Versus Conversations to Improve HPV Vaccination Coverage: A Randomized Trial. Pediatrics 2016, 139, e20161764. [CrossRef] [PubMed]</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_tYs9tmT">Effect of a Text Messaging Intervention on Influenza Vaccination in an Urban, Low-Income Pediatric and Adolescent Population: A randomized controlled trial</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">O</forename><surname>Kharbanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Stockwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Vargas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Vawdrey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Camargo</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2012.502</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_m2KqRy8">JAMA</title>
		<imprint>
			<biblScope unit="volume">307</biblScope>
			<biblScope unit="page" from="1702" to="1708" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kharbanda, E.O.; Stockwell, M.S.; Martinez, R.A.; Vargas, C.Y.; Vawdrey, D.K.; Camargo, S. Effect of a Text Messaging Intervention on Influenza Vaccination in an Urban, Low-Income Pediatric and Adolescent Population: A randomized controlled trial. JAMA 2012, 307, 1702-1708. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_ZRj2pNp">An Emergency Department-based Vaccination Program: Overcoming the Barriers for Adults at High Risk for Vaccine-preventable Diseases</title>
		<author>
			<persName><forename type="first">D</forename><surname>Rimple</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Ernst</surname></persName>
		</author>
		<idno type="DOI">10.1197/j.aem.2006.04.022</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nTwQvBY">Acad. Emerg. Med</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="922" to="930" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rimple, D.; Weiss, S.J.; Brett, M.; Ernst, A.A. An Emergency Department-based Vaccination Program: Overcoming the Barriers for Adults at High Risk for Vaccine-preventable Diseases. Acad. Emerg. Med. 2006, 13, 922-930. [CrossRef] [PubMed]</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_2r2EWr6">For the CONSORT Group Consort 2010 statement: Extension to cluster randomised trials</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Piaggio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Elbourne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.e5661</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Y8UgNCK">BMJ</title>
		<imprint>
			<biblScope unit="volume">345</biblScope>
			<biblScope unit="page">5661</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Campbell, M.K.; Piaggio, G.; Elbourne, D.R.; Altman, D.G. For the CONSORT Group Consort 2010 statement: Extension to cluster randomised trials. BMJ 2012, 345, e5661. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<idno type="DOI">10.1016/b978-2-294-00922-8.50001-7</idno>
		<ptr target="https://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/etudes-et-resultats/article/les-personnes-agees-aux-urgences-une-patientele-au-profil-particulier" />
		<title level="m" xml:id="_xhqd6vu">Les Personnes âgées aux Urgences: Une patientèle au Profil Particulier-Ministère des Solidarités et de la Santé</title>
		<imprint>
			<date type="published" when="2020-12-10">10 December 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Les Personnes âgées aux Urgences: Une patientèle au Profil Particulier-Ministère des Solidarités et de la Santé. Available online: https://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/etudes-et-resultats/article/les-personnes- agees-aux-urgences-une-patientele-au-profil-particulier (accessed on 10 December 2020).</note>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<idno type="DOI">10.1016/j.medmal.2019.04.364</idno>
		<title level="m" xml:id="_mBbsm4r">Données de Couverture Vaccinale Grippe par Groupe d&apos;âge. Available online: /determinants-de-sante/vaccination/donnees</title>
		<imprint>
			<date type="published" when="2020-12-10">10 December 2020</date>
		</imprint>
	</monogr>
	<note type="report_type">-decouverture-vaccinale-grippe-par-groupe-d-</note>
	<note type="raw_reference">Données de Couverture Vaccinale Grippe par Groupe d&apos;âge. Available online: /determinants-de-sante/vaccination/donnees-de- couverture-vaccinale-grippe-par-groupe-d-age (accessed on 10 December 2020).</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_P38fy4T">Risk factors for community-acquired pneumonia in adults in Europe: A literature review</title>
		<author>
			<persName><forename type="first">A</forename><surname>Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Peetermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Viegi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Blasi</surname></persName>
		</author>
		<idno type="DOI">10.1136/thoraxjnl-2013-204282</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W9eFpNj">Thorax</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1057" to="1065" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Torres, A.; Peetermans, W.E.; Viegi, G.; Blasi, F. Risk factors for community-acquired pneumonia in adults in Europe: A literature review. Thorax 2013, 68, 1057-1065. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_ttbQghY">For the French Society of Emergency Medicine Evaluation and Quality Committee the French Emergency National Survey: A description of emergency departments and patients in France</title>
		<author>
			<persName><forename type="first">D</forename><surname>Naouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>El Khoury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vincent-Cassy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vuagnat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yordanov</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0198474</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Ww92Nex">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">198474</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Naouri, D.; El Khoury, C.; Vincent-Cassy, C.; Vuagnat, A.; Schmidt, J.; Yordanov, Y. For the French Society of Emergency Medicine Evaluation and Quality Committee the French Emergency National Survey: A description of emergency departments and patients in France. PLoS ONE 2018, 13, e0198474. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_Mm9phAr">Vaccination practices in U.S. emergency departments, 1992-2000</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Pallin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Muennig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Emond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Camargo</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2004.06.053</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZzBDMW2">Vaccine</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1048" to="1052" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pallin, D.J.; Muennig, P.A.; Emond, J.A.; Kim, S.; Camargo, C.A. Vaccination practices in U.S. emergency departments, 1992-2000. Vaccine 2005, 23, 1048-1052. [CrossRef] [PubMed]</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_hd4xd9y">Increasing Influenza and Pneumococcal Vaccination Uptake in Seniors Using Point-of-Care Informational Interventions in Primary Care in Singapore: A Pragmatic, Cluster-Randomized Crossover Trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y.-R</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Koh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Y</forename><surname>Tham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Anwar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S H</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Y T</forename><surname>Mcfps</surname></persName>
		</author>
		<idno type="DOI">10.2105/ajph.2019.305328</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CrE9MZ6">Am. J. Public Health</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="1776" to="1783" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ho, H.J.; Tan, Y.-R.; Cook, A.; Koh, G.; Tham, T.Y.; Anwar, E.; Chiang, G.S.H.; Lwin, M.; Chen, M.I.; McFps, T.Y.T.; et al. Increasing Influenza and Pneumococcal Vaccination Uptake in Seniors Using Point-of-Care Informational Interventions in Primary Care in Singapore: A Pragmatic, Cluster-Randomized Crossover Trial. Am. J. Public Health 2019, 109, 1776-1783. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_F9fA9Cs">Patient reminder and recall interventions to improve immunization rates</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C J</forename><surname>Vann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Coyne-Beasley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Asafu-Adjei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Szilagyi</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd003941.pub3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DKEUg2j">Cochrane Database Syst. Rev</title>
		<imprint>
			<biblScope unit="page">3941</biblScope>
			<date type="published" when="2018">2018. 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vann, J.C.J.; Jacobson, R.M.; Coyne-Beasley, T.; Asafu-Adjei, J.K.; Szilagyi, P.G. Patient reminder and recall interventions to improve immunization rates. Cochrane Database Syst. Rev. 2018, 2018, CD003941. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_svUZ3MZ">Text messaging reminders for influenza vaccine in primary care: A cluster randomised controlled trial (TXT4FLUJAB)</title>
		<author>
			<persName><forename type="first">E</forename><surname>Herrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Van Staa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ranopa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Free</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chadborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Goldacre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Smeeth</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2015-010069</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ahCvztV">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">10069</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Herrett, E.; Williamson, E.; Van Staa, T.; Ranopa, M.; Free, C.; Chadborn, T.; Goldacre, B.; Smeeth, L. Text messaging reminders for influenza vaccine in primary care: A cluster randomised controlled trial (TXT4FLUJAB). BMJ Open 2016, 6, e010069. [CrossRef] [PubMed]</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_6t2GpSC">Randomized Controlled Trial of Text Message Reminders for Increasing Influenza Vaccination</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Regan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bloomfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">V</forename><surname>Effler</surname></persName>
		</author>
		<idno type="DOI">10.1370/afm.2120</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PudFabG">Ann. Fam. Med</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="507" to="514" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Regan, A.K.; Bloomfield, L.; Peters, I.; Effler, P.V. Randomized Controlled Trial of Text Message Reminders for Increasing Influenza Vaccination. Ann. Fam. Med. 2017, 15, 507-514. [CrossRef] [PubMed]</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_bCTu9rS">Attitudes, knowledge, and willingness to be vaccinated against seasonal influenza among patients hospitalized with influenza-like-illness: Impact of diagnostic testing</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tubiana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Launay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Galtier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tattevin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Postil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vanhems</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lenzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Verger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Duval</surname></persName>
		</author>
		<idno type="DOI">10.1080/21645515.2019.1674598</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pdeuTy5">Hum. Vaccines Immunother</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="851" to="857" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tubiana, S.; Launay, O.; Galtier, F.; Tattevin, P.; Postil, D.; Vanhems, P.; Lenzi, N.; Verger, P.; Duval, X. Attitudes, knowledge, and willingness to be vaccinated against seasonal influenza among patients hospitalized with influenza-like-illness: Impact of diagnostic testing. Hum. Vaccines Immunother. 2020, 16, 851-857. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_xmpHnA7">Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency</title>
		<author>
			<persName><forename type="first">P</forename><surname>Loubet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kernéis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Groh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Loulergue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Blanche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Verger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Launay</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2015.06.012</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SW6ccHX">Vaccine</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="3703" to="3708" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Loubet, P.; Kernéis, S.; Groh, M.; Loulergue, P.; Blanche, P.; Verger, P.; Launay, O. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine 2015, 33, 3703-3708. [CrossRef] [PubMed]</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_8cq2CbM">Perceptions of influenza and pneumococcal vaccine uptake by older persons in Australia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Briggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fronek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wilde</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2019.06.079</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fSevBCq">Vaccine</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="4454" to="4459" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Briggs, L.; Fronek, P.; Quinn, V.; Wilde, T. Perceptions of influenza and pneumococcal vaccine uptake by older persons in Australia. Vaccine 2019, 37, 4454-4459. [CrossRef] [PubMed</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
